Compare MTW & RIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTW | RIGL |
|---|---|---|
| Founded | 1902 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 406.4M | 537.6M |
| IPO Year | N/A | 2000 |
| Metric | MTW | RIGL |
|---|---|---|
| Price | $12.18 | $43.40 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | $10.25 | ★ $43.20 |
| AVG Volume (30 Days) | 222.5K | ★ 654.6K |
| Earning Date | 11-05-2025 | 11-04-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 2698.26 |
| EPS | 1.58 | ★ 6.20 |
| Revenue | ★ $2,159,800,000.00 | $282,076,000.00 |
| Revenue This Year | $0.28 | $65.53 |
| Revenue Next Year | $6.14 | $0.22 |
| P/E Ratio | $7.77 | ★ $7.00 |
| Revenue Growth | N/A | ★ 79.13 |
| 52 Week Low | $7.06 | $14.63 |
| 52 Week High | $13.62 | $52.24 |
| Indicator | MTW | RIGL |
|---|---|---|
| Relative Strength Index (RSI) | 65.64 | 52.26 |
| Support Level | $11.11 | $43.81 |
| Resistance Level | $11.41 | $49.96 |
| Average True Range (ATR) | 0.38 | 3.82 |
| MACD | 0.13 | -0.53 |
| Stochastic Oscillator | 81.82 | 33.11 |
Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.